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170 Chapter 14
The studies described in this thesis focused on three main subjects;
- the pathophysiology of sickle cell vaso-occiusion,
- novel markers for assessing sickle cell disease (SCD) severity,
- potential therapeutics for sickle cell patients.
The main findings are summarized in the following paragraph. Related furure
perspectives for research aÍe presented thereafter.
1..1. Sumnary
Chapter 2 encompasses a general overview of SCD r . Next to its pathophysiological
basis, the major complications and its general management are discussed. AIso,
the complexity of risk assessment for poor outcome is addressed. The frequency
of acute vaso-occlusive events is often used as a marker of disease severity in
patients with SCD. Based upon our own experience, as well as on findings in
the literature, we suggest that for the majority of patients, monitoring therapy
efficacy and assessing disease severity by only scoring the frequency of such
events may not be accurate 2' r. In order to describe the vaso-occlusive process
more accurately, we propose three levels of vaso-occlusion in chapter 3, namely
silent-, non-clíníca.l-, and clínícql vqso-occlusíon a. The fact that even patients who
seldomly require medical care acquire significant organ damage throughout life
and have a decreased life expectancy, underscores the impact of both non-clinial
and sllent vaso-occlusion on the morbidity and mortaliry in SCD. Based upon the
increasing understanding of the pathophysiology of sickle ce1l vaso-occlusion,
we discuss several novel potential rnarkers that may prove to reflect the silent
vaso-occlusive process in SCD. Also, potential therapeutic strategies based on
current insights into the pathogenesis of sickle cell vaso-occhrsion (such u
anticoagulation and B-vitamin suppiementation), are presented'.
ln chapter 4 a role for interleukin-S (lL-S), a neutrophil chemotactin, in the
pathogenesis of clinical vaso-occlusion in sickle cell patients is demonstrated'.
Patients presenting with a painful crisis were characterized by strongly elevated
IL-8 levels, irrespective of the crisis inducing factor. With amelioration f
symptoms IL-8 levels dropped to levels comparable to those in healthy confolr
As the Duffy antigen receptor for chemokines on red biood ce1ls binds ad
inactivates IL-8, we investigated whether a Duffy-positive phenotype is protctttt
for clinical vaso-occlusion ('8. No difference in ciinical vaso-occlusion couldh
detected between Duffy-negative and Duffy-positive adult sickle cell patio8
(chapter 5) '. The finding of a significantly higher upward deviation of meanllf
levels in Duffy-negatives as opposed to Ouffy positives suggests that IL-8 blood
Ievels are more tightly regulated in Duffy positive sickle cell patients.
Endothelial activation is an integral part ofthe sickle cell vaso-occlusiveprrr6
1'). We investigated if the degree of endothelial activation, as measured bysolu&
vascular cell adhesion molecule-1 (sVCAM-1) serum levels, is indicativeofL
occurrence of clinical vaso-occlusion in SCD. As described in chaphr 6
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inversely related to henroglobin levels in this patient group. Given the
0f VCAM-1 interactions with the very late activating antigen-4 on erythroid
itors and reticulocytes in erythropoiesis, a potential relationship of
Related future
AM-l to hematopoietic growth factors was investigated12' 11. sVCAM-1 levels
not correlate significantly to interleukin-3, granulocl'te-macrophage colony
factor or ervthropoietin serum levels, or to serum levels of the soluble
rin receptor (chapter 4 " .In chapter 8 a statistically significant coïÍelation
M-l levels with plasma von Willebrand factor (vWF) levels (which to our
is not involved in erythropoiesis) is described 15. Based upon these
we conclude that serum sVCAM-1 levels most likelv reflect vascular
activation in sickle cell patients.
investigated whether decreased plasma levels of naturally occurring
nts protein C and S are associated with clinical vaso-occlusion in
8 15. The more severe phenotype of SCD (HbSS) was characterized
he more severe derangement of protein C and S levels (as compared to
patients). Apart from slightly lower protein C in HbSC patients who had
clinical vaso-occlusion in the vears prior to sanrnle collection. no
was detected betlveen patients tirat did, or did not experience clinical
n. There was a significant inverse correlation between sVCAM-
and both free and total protein S levels, and there was a significant
conelation between total protein S leveis and hemoglobin levels in HbSS
nitric oxide availability is currently regarded to be of importance in
plications of SCD 1". In chapter 9we demonstrated that arginine
seems to be shifted to the arginase pathway in HbSS patients, with
of this shift being greater in patients with lower hemoglobin levels
Ieukocyte counts 17. The increased demand for polyamines for red
cell produclion (and perhaps also for repair of continuously damaged
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higher in our pediatric patients 20. The lowest achievable homocysteine level was
determined by supplementing high doses of folic acid, vitamin B.. aud vitamin
8,,2a. Subsequently, the optirnal daily dose of folic acid, vitamin Bo andvitamin
B,, supplementation in order to achieve this target homocysteine level was
determined (chapter 13)')5.
1.2 Future perspectives
In this tiresis we described the irnportance of accurately assessing SCD severity
for the management of patients with this debilitating disease. Monitoring the
effect of (experimental) therapies by solely assessing the effect on clinical vaso.
occlusion is inaccurate, as neither the rate of accumulating organ damage, nor
mortality, are related to the frequency of clinical vaso-occlusion in most sick.le cell
patients 4.
We attempted to investigate whether several laboratory markers linked to the
pathophysiology of vaso-occlusion could be useful as parameters for assessing
SCD severity. The interpretation of the results of our and other comparable
studies is limited by several factors. Firstly, disease severity is often arbitrarily
defined. Some studies combine hentatological characteristics (such as the
percentage of fetal hemoglobin [HbF%] and hemoglobin levels) with cliniai
vaso-occlusion, whereas others only use clinical vaso-occlusion as an indication
of disease severity 26're. In some studies only clinical vaso-occlusion that requira
hospitalization is scored as a vaso-occlusive event, whereas otlter studies also
include emergency room visits 2, ][ts. Sometimes laboratory data, the rate of
clinical vaso-occlusion as well as infectious complications are combined r.
Secondly, for accurately assessing the value of both established (such as the
HbFo/") and potential lsuch as serum sVCAM-1 levels) markers of disease severity,
all levels ofvaso-occltrsion (clinicai, non-clinical and silent vaso-occlusion) should
be monitored. Thirdly, many studies, inciuding ours, are retrospective. Selection
bias occurs when associations of novel potential markers of disease severityan
studied in this manner, as blood samples of deceased patients are mostly nd
available for laboratory testing.
Institution of specialized sickle cell medical centers, such as in the U.SÁ,
England and Jamaica, has not otily improved patient care, but also providedthc
infrastructure for much needed epidemiological and pathophysiological resaró
r7 r'[). In order to minimize tire caveats outlined above, we are currently centaliziq
the out-patient care for sickle cell patients in Curagao. Both pediatric and a&l
patients will be seen at a specialized 'out-patient sickle cell center'. In this seli4
all patients (and/or their parents when applicable) will be asked to give infornd
consent to participate in a prospective cohort study in order to betterdefineh
patients disease course. In order to assess non-clinical vaso-occlusion, paticË
will be asked to keep pain diaries at home a0. For analyzing the extent to rfr
silent vaso-occlusion occurs, it seems imoerative to determine the exEnild
ischemic organ damage and dysfunction wiih objective diagnostics tools (srtl
imaging studies and specific organ function testing) 41'1r. As acute care forsilh
cell patients in Curagao is almost exclusively confiued to one hospital,rrÍd
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complications r' ' . Perhaps monitoring of ADAMTSl3 in patients
painful events may help to predict the SCD-MOF syndrome and allow
of aggressive interrrentions.
pediatric and rf+ traits that may influence the outcome of sickle cell patients are currently
:nte/. In this intensive r search. For example, specific polymorphisms of the VCAM-
ced to give inlon
'to better dc6a
maybe associated with a reduced risk of stroke, and patients with nitric
gene polymorphisms may have an increased susceptibility to the
r-ocdusion'
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hat we can accurately lneasure clinical, non-clinical and silent vaso-occlusion
u such a setting. Standard hematological, biochemical, and organ function
hts, as well as selected imaging studies will be performed at pre-determined
nhrvals, and blood samples will be stored centrally for subsequent laboratory
ludies. Hopefully, this cornprehensive approach will not only provide us with
nwinsights into SCD pathophysiology and objective additive tools for managing
Nklecell patients, but will optirnize the care and guidance of patients and their
hrilies as well aa' *t.
potential laboratorT parameters should be studied as markers for assessing
vaso-occlusive disease severity in SCD) Increasing insights into vascular
is are not only unraveling the many futrctions of endothelial cells,
also provide us with several potential parameters for assessing endothelial
and damage in SCD. For example, next to rnonitoring soluble markers
as svcAM-1, characterization and enumeration of circulatins endothelial
provide moÍe accurate informatiou on tire extent of endothelial damage
a6oe. Also, novel biornarkers of tissue ischerniia are beins develi g loped, such
.modified albunrin, which should be studied in SCD 50.
0ther laboratory tools that are of interest for predicting the occurrence of
complications include hemostatic profiles. Indeed, plasma D-
Ievels have been shown to be associated with the occurrence of clinical
ion in both a retrospective as well as a prospective setting 5r, 52. The
of the SCD multi-organ failure (SCD-MOF) syndrome to thrombotic
nic purpura (TTP), together with reports of reversal of SCD-
wrth plasmapheresis, suggests a potential common denominator in these
syndromes 5r ):-. Central to the pathogenesis of TTp is a redr-rced
of ADAMTSl3 (a disintegrin-like and rnetalloprotease domain with
in q'pe I motifs), which cleaves the thrombogenic unusually large
multimers upon their release from activated endothelial ce1ls ss. As
been shown that UL-vWF multimers also mediate the adhesion of sickle
celis (SRBC's) to endothelial cel1s in vítro, we are currently studying if
activity ofADAMTSl3 is associated with the occlrrrence of SCD related
syndrome (ACS1 un"'. It is generally accepted that monitoring disease
blood levels of soluble factors such as cytokines, adhesion molecules
factors is challenging. Such soluble factors can display biological
wrth time and within individuals, and their levels may not accuratelv
concentÍation r effect at a site of tissue ifliury cr; c+. However. SCD is
rne hospital by continuous vaso-occlusion leading to endothelial activation and
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damage in the vascular beds of virtually all organs. Therefore, through careful
selection of parameters that are widely and continuously expressed on activated
endothelium, measuring soluble factors may prove of value in monitoring the
vaso-occiusive process in SCD. Pertaining to sVCAM-1, we have provided ata
indicating its potential as a rnarker for monitoring endothelial activation in SCD,
although \À/e cannot definitively rule out that sVCAM-1 levels are also determined
in part by stress eq.'thropoiesis 11: lar ts. New studies have shown that sVCAM-l
levels correiate to specific organ dysfunction in sickle cell patients, and a recent
study has shown that HbF induction, which is known to reduce (clinical) vaso.
occlusion, was associated with a decrease not only in sVCAM-1 levels, but also in
vWF levels, inflammatory markers and hypercoagulability during the clinically
asymptomatic state 65 66. As an induction of HbF also attenuates hemolysrs,
it remains possible that the sVCAM-1 reduction reflects a reduction of both
endothelial activation (and perhaps silent vaso-occlusion) and erythropoiesis io ó:.
Studies in large and accurately described populations should further address the
potential of markers of endotheliai activation for rnonitoring the vaso-occlusive
process, taking into account their relation to ail levels of vaso-occlusion, the
inter- and intra-patient variability, as well as their ability to predict poor outcorne.
Measuring endothelial activation markers in stored serum and plasma samplesof
previously described cohort studies will likely be the most appropriate strategy.
The increasing understanding of the pathogenesis of sickle cell vaso-occlusion
has shifted its paradigm from simple obstruction of blood vessels by SRBC'sto
a highly complex mechanisrn in which most q?es of blood cells, the coagulation
cascade, the endothelium and inflammatory mediators are involved (see figure lf
16:68-70. This has provided us with new potential therapeutic targets for managhg
SCD. Given the many factors involved in the vaso-occlusive process of SCD,
targeting multiple pathophysiological pathways may have a synergistrc dinial
effect. A case in point is hydroxyurea; whereas its beneficiary effect was initially
thought to be solely attributable to HbF induction, it is now clear that reductionof
neutrophiiic granuiocytes via myelosuppression, as well as (directly or indirecdyf
reduced erythrocyte-endothelial adhesion aiso are of importance 71 n. As vaso
occlusion occurs continuously even in clinically asymptomatics, therapeutic
aimed at preventing or reducing organ damage should be taken lifelong ad
should reduce silent and (non) clinical vaso-occlusion '. Throughout agred
part of their life, many patients may be relatively symptom free, thus rEutrug
such therapeutics to be simple in use and to have minimal side effects. lnÈb
light, it should be realized that the greatest burden of SCD occurs in developi{
countries, with about 120,000 chrldren born with a form of SCD per year in Afrb
(as opposed to 1,000 newborns with SCD per yeaï in the Untted States ofAmsbl
70. It is surprising that optimism about curÍent and experimental thenpia
for SCD is not counterbalanced by the fact that few accepted therapeutia rn
applicable in financially stricken developing countries 7s. Therefore, we shail
utilize our 'high-tech diagnostics to study and deveiop management s ratgb
that ultirnateiy have the potential to benefit patients globally.
Figure 1
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Èe coming months, an intervention study with oral N-acetylcysteine (NAC)
I be conducted in curagao. NAC is an antioxidant with pleiotropic anti-
ry effects, and oral supplementation with NAC replenishes reduced
gluthation stores in sickle cell patients (gluthation is the most abundant
&ondant i  our body and forms an important defense against free radicals) 76'
,Reactive oxygen species play an important role in the pathophysiology of SCD
endothelial damage via reperfusion injury and NAC administration to
ients with SCD may be of benefit via multiple mechanisms 76' 7t-8r. Examples
promising therapeutics for SCD that are currently being studied by other
include supplementation of arginine, zinc and n-3 fatty acids, as well
dotimazole and magnesium salts in order to reduce red cell dehydration
lAlso, inhibition of nuclear factor rcB (a transcription factor that regulates
important proteins involved in the vaso-occlusive process of SCD) witn
is currently being investigated ' ^ sE.
what of anticoagulation as a therapy for SCDI In simple painful crises, the
ion of fibrin formation in the microvasculature may be limited and
secondarily to adhesion of SRBC's and leukocytes to endothelial cells 1e.
to be seen whether anticoagulation pÍevents such events (or reduces
6e. Whereas hydroxyrrrea prevents the occurrence of both painful
andACS's, it may be less effective in preventing ischemic strokes, which
characterized by large vessel thrombosis 68' 8e'ea. Given the burden and
tofchronic transfusion therapy, a randomized controlled trial comparing red
hnsfusions to anticoagulation in high-risk pediatric patients for ischèmic
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stroke seems justified. Also, thrombosis of pulmonary vasculatuÍe may contÍibute
to the development and progression of chronic sickle cell lung disease, which rs
characterized by pulmonary fibrosis and pulmonary hypertension, and has a
very poor prognosis es101. It is estimated to occur in at least 30% of adult sickle
cell patients 100i rÍ)2. We will conduct a study in which, with modern pitlmonary
imaging techniques and echocardiography, the presence of pulmonary
hypertension and pulmonary vascular occlusion will be assessed. If a decreased
pulmonary vascular patency is associated with pulmonary hypertension in these
patients, intervention studies with anticoagulation wili foliow. As in any study
regarding anticoagulation, the fear of bleeding complications will necessitate
stringent inclusion criteria. However, with the advent of newer and possibly safer
anticoagulants, the potential role of anticoagulation, especially for prevenhon
of such major complications as described above, should be investigated 10r.
Interestingly, heparin has been shown to reduce SRBC-endothelial cell adhesion,
making this an interesting option for therapeutic trials in SCD 104'107.
Given the central role of the sickling process in the pathophysiology of vaso.
occlusion, it is clear that for long-term pharmacological management of
SCD, the single most effective way to reduce vaso-occlusion would be to
limit HbS polymerization. As shown in our work, the extent to which several
pathophysiological processes occur is related to the degree ofanemia, and based
upon large studies, lower hemoglobin levels are associated with many SCD
related complicationt 1; 11; 15; 17; 108. An exception is the pain-rate and ACS frequency,
indicating that relatively high hemoglobin levels without concomitant HbF or
HbAr"/" increments result in a higher rate of clinical vaso-occlusion 2' 6. The
effect of anemia on silent vaso-occlusion, however, may be the opposite in specific
organs as exemplified by the higher risk of ischemic small and large vessel brain
injury in absence of overt stroke in patients with relatively lower hemoglobin
levels 110' 11r. It is also important to realize that, even though the work in this thesis
focused mainly on vaso-occlusion, the hemolytic anemia, with its concomitant
hernodynamic changes, is not only a symptom of SCD, but in manyways anaioÍ
contributor to the pathology observed in these patients. This is supportedbythe
fact that in patients with symptomatic thalassemia the incidence of pulmonary
hypertension, strokes and leg ulcers is aiso high 112, 11r. Furthermore, thalassemia
patients (but also patients with other forms of hemolytic anemia) are dso
characterized by a hypercoagulable state and endothelial activationrrHlT
Currently, HbF inducing agents (such as butyrate and decitabine) are underactive
investigation as anti-sickling agents tt8. However, it does not seem conceivable
that, in the near future, effective red cell sickling prevention will be either widely
applicable, or by rtself sufficient to effectively prevent organ damaget. Bone
marrow transplantation, which can cure SCD, remains a high-risk procdun
that is unlikely to benefit most sickie cell patients. Therefore, itislikelythatr
combination of several different drugs targeting rnultiple pathways involved in
the vaso-occiusive process will be needed for effective long-term managementof
most sickle cell patients. If the different pathophysiological mechanisms invohd
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heconcepts and through the increasing collaborative work with our colleagues
&oad, we hope that in the coming years we will contribute to improvins the
of patients with SCD.
nvaso-occlusion are further characterized and their importance in relation to
developing organ damage can be established, risk assessment can be optimized,
udindividuali"ed therapeutic regimens could become daily practice. perhaps in
fiefuture, asa form of 'vascular endotheiiai supportive ."r"', 
" 
widely appliiable
lngt 'sickle cell pilL will consist of anti-oxidants, B-vitamins, and àrginine.
luch a pill could also be used next to an anti-red ce[ dehydration agent, an HbF
nducing a ent, an anti-inflarnmatory agent and/or perhaps an inticoagulant
hpending on the risk profile of the patÈnt. However, before such theraoeutrc
ttategies can be developed, randomized controlled trials shouid be perforÁed inqdertoestablish their individual and combined efficacies. Importantly. previous
firdies regarding therapeutic intervention in SCD, such as wrth hyáàryrrea,
miyincluded patients with frequent episodes of clinical vaso-occlusion in order
hbeable to reach clinical endpoints 8e. By doing so, we fail to study the potential
dsuchtherapeutics in the majority ofpatients rir. If therapeutic interveniions are
bbe studied in the general sickle cell population, future srudies should measure
dinical, non clinical, and ideally, silent vaso-occlusion o. ïrerefore, the search
fuaccurate markers of silent vaso-occlusion is of cardinal importance. Based on
